Alain Beck

Dr Alain Beck is Senior Director, Biologics CMC and Developability (Pierre Fabre), Associate Editor of mAbs (2009) and chairman of MabDesign SAB (2014). He is or was involved in 10 clinical stage biologics R&D programs including dalotuzumab (Merck), telisotuzumab/ telisotuzumab vedotin (AbbVie), lonigutamab ugodotin ADC and W0180 mAb (PF), ER004 Fc-fusion protein (www.esperare.org) and VB421/ lonigutamab (www.valenzabiotech.com). He is author/ co-author of +250 publications (h-index: 60; +13,500 citations). He has contributed to +300 scientific meetings (AIS, BAS, Bioproduction, CASSS, CTDP, EAC, FOB, GlycoBiotec, PEGS, SCT, WADC, WBC, WCBP) as chairman, invited speaker, panellist, moderator, advisor, and/or organizer (IO mAbs, ADCs, Biobetters, Biosimilars, pAbs, Bs/MsAbs, Fc-fusions, Protein Scaffolds, Mass Spec, Med Chem, PK/PD, separative sciences). He was ranked 6/50 global antibody industry influencers (2013) and is the 6th World ADC Awards winner for long standing contribution to the field (2019). He is member of the MAB Working Party (EDQM/PhEur) and involved in meetings with ANSM, EU, EMA, FDA, NIST, USP and WHO.